Name | Palm Bay Hospital |
---|---|
Type | Acute Care Hospital |
Location | 1425 Malabar Rd, Ne, Palm Bay, Florida |
Ownership | Proprietary |
Emergency Services | Yes |
Medicare ID (CCN) | 100316 |
NPI Number | 1386940823 |
Organization Name | HOLMES REGIONAL MEDICAL CENTER, INC |
Doing Business As | PALM BAY HOSPITAL |
Address | 1425 Malabar Rd Ne, Palm Bay, FL 32907 |
Hospital Type | General Acute Care Hospital |
Phone Number | 321-434-8000 |
News Archive
BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that 2014 was a record year for its eClinical technologies business unit, with sales soaring 51 percent above the previous year.
A study led by researchers at Beth Israel Deaconess Medical Center, in collaboration with scientists at Walter Reed Army Institute of Research, Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson and Gilead Sciences, Inc., has demonstrated that combining an experimental vaccine with an innate immune stimulant may help lead to viral remission in people living with HIV.
The development of new antiviral drugs has had a tremendous impact on the quality of life and life expectancy of HIV-positive and AIDS patients, as the drugs effectively disrupt the replication cycle of the HIV virus. Yet the regular use of those drugs - such as zidovudine (also known as azidothymidine or AZT), protease inhibitors, and highly active antiretroviral therapy (HAART) involving multidrug therapies - has led to resistant HIV strains.
Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.
› Verified 4 days ago
NPI Number | 1467779496 |
Organization Name | PALM BAY HOSPITAL, INC. |
Address | 1425 Malabar Rd Ne, Palm Bay, FL 32907 |
Hospital Type | General Acute Care Hospital |
Phone Number | 321-722-8000 |
News Archive
BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that 2014 was a record year for its eClinical technologies business unit, with sales soaring 51 percent above the previous year.
A study led by researchers at Beth Israel Deaconess Medical Center, in collaboration with scientists at Walter Reed Army Institute of Research, Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson and Gilead Sciences, Inc., has demonstrated that combining an experimental vaccine with an innate immune stimulant may help lead to viral remission in people living with HIV.
The development of new antiviral drugs has had a tremendous impact on the quality of life and life expectancy of HIV-positive and AIDS patients, as the drugs effectively disrupt the replication cycle of the HIV virus. Yet the regular use of those drugs - such as zidovudine (also known as azidothymidine or AZT), protease inhibitors, and highly active antiretroviral therapy (HAART) involving multidrug therapies - has led to resistant HIV strains.
Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.
› Verified 4 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that 2014 was a record year for its eClinical technologies business unit, with sales soaring 51 percent above the previous year.
A study led by researchers at Beth Israel Deaconess Medical Center, in collaboration with scientists at Walter Reed Army Institute of Research, Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson and Gilead Sciences, Inc., has demonstrated that combining an experimental vaccine with an innate immune stimulant may help lead to viral remission in people living with HIV.
The development of new antiviral drugs has had a tremendous impact on the quality of life and life expectancy of HIV-positive and AIDS patients, as the drugs effectively disrupt the replication cycle of the HIV virus. Yet the regular use of those drugs - such as zidovudine (also known as azidothymidine or AZT), protease inhibitors, and highly active antiretroviral therapy (HAART) involving multidrug therapies - has led to resistant HIV strains.
Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.
› Verified 4 days ago
Palm Bay Hospital Acute Care Hospital Location: 1425 Malabar Rd, Ne, Palm Bay, Florida 32907 Phone: (321) 434-8000 |